Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes

Benzinga12-13

On Thursday, Corcept Therapeutics Incorporated (NASDAQ:CORT) said that the primary endpoint was met in the treatment phase of CATALYST, a randomized, double-blind, placebo-controlled study of Korlym ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2491780413?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/e1h7CWrKKwNVUMxbKgiltg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/ece19e53408aeb62e0f73a92c9753b9a","is_english":true,"pubTime":"2024-12-13 21:53","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2491780413","market":"us","top_or_hot":-1,"title":"Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes","media":"Benzinga","content":"<div>\n<p>On Thursday, Corcept Therapeutics Incorporated (NASDAQ:CORT) said that the primary endpoint was met in the treatment phase of CATALYST, a randomized, double-blind, placebo-controlled study of Korlym ...</p>\n\n<a href=\"https://finance.yahoo.com/news/corcept-therapeutics-fda-approved-korlym-135308960.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-13 21:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/corcept-therapeutics-fda-approved-korlym-135308960.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Thursday, Corcept Therapeutics Incorporated (NASDAQ:CORT) said that the primary endpoint was met in the treatment phase of CATALYST, a randomized, double-blind, placebo-controlled study of Korlym ...</p>\n\n<a href=\"https://finance.yahoo.com/news/corcept-therapeutics-fda-approved-korlym-135308960.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1559883803.SGD","symbol_name":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","start_time":0,"source_url":"https://finance.yahoo.com/news/corcept-therapeutics-fda-approved-korlym-135308960.html","article_id":"2491780413","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/e1h7CWrKKwNVUMxbKgiltg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/ece19e53408aeb62e0f73a92c9753b9a"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491780413","pubTimestamp":1734097988,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"On Thursday, Corcept Therapeutics Incorporated  said that the primary endpoint was met in the treatment phase of CATALYST, a randomized, double-blind, placebo-controlled study of Korlymin patients with hypercortisolism  and difficult-to-control type 2 diabetes.Hypercortisolism is caused by excessive activity of the hormone cortisol. Symptoms vary, but most patients experience one or more of the following manifestations: hypertension, central obesity, elevated blood sugar and difficult-to-control type 2 diabetes, severe fatigue, and weak muscles.Also Read: Corcept Therapeutics’ Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast. CATALYST is a prospective Phase 4 study with two parts. The first part assessed the prevalence of hypercortisolism by screening 1,057 patients with difficult-to-control type 2 diabetes, defined as hemoglobin A1c greater than 7.5% despite receiving optimal therapies, including GLP-1 agonists.Patients who received Kor","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","BK4532":"文艺复兴科技持仓","CORT":"Corcept医疗","BK4007":"制药","LU0566484027.USD":"安本美国小盘成长股"},"translate_title":"Corcept Therapeutics获得FDA批准的Korlym在患有难以控制糖尿病的库欣综合征患者中达到了主要目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":1},"content_text":"On Thursday, Corcept Therapeutics Incorporated (NASDAQ:CORT) said that the primary endpoint was met in the treatment phase of CATALYST, a randomized, double-blind, placebo-controlled study of Korlym in patients with hypercortisolism (Cushing’s syndrome) and difficult-to-control type 2 diabetes.\nHypercortisolism is caused by excessive activity of the hormone cortisol. Symptoms vary, but most patients experience one or more of the following manifestations: hypertension, central obesity, elevated blood sugar and difficult-to-control type 2 diabetes, severe fatigue, and weak muscles.\nAlso Read: Corcept Therapeutics’ Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast\nCATALYST is a prospective Phase 4 study with two parts. The first part assessed the prevalence of hypercortisolism by screening 1,057 patients with difficult-to-control type 2 diabetes, defined as hemoglobin A1c greater than 7.5% despite receiving optimal therapies, including GLP-1 agonists.\nThe primary endpoint was the reduction in hemoglobin A1c between these groups. CATALYST met its primary endpoint.\nPatients who received Korlym exhibited a clinically meaningful and statistically significant improvement in hemoglobin A1c, with a decrease from baseline of 1.47% compared to a decrease of 0.15% in patients who received a placebo.\nComplete results from CATALYST will be presented at a medical conference next year.\nThe safety profile of Korlym was consistent with the medication’s label, and no new side effects or adverse events were identified.\nIn February 2012, the company introduced Korlym, the first medication approved by the FDA to treat patients with endogenous hypercortisolism.\nPrice Action: CORT stock traded higher by 2.09% at $57.50 premarket at the last check Friday.\nRead Next:\n\nT-Mobile’s Premium Valuation Prompts Downgrade As Growth Projections Decelerate: Analyst\n\nPhoto via Shutterstock.\nUp Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.\nGet the latest stock analysis from Benzinga?\n\nCORCEPT THERAPEUTICS (CORT): Free Stock Analysis Report\n\nThis article Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes originally appeared on Benzinga.com\n© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2491780413"}